Emerging Researchers National (ERN) Conference

nsf-logo[1]

  • About
    • About AAAS
    • About the NSF
    • About the Conference
    • Partners/Supporters
    • Project Team
  • Registration
    • Conference Registration
    • Exhibitor Registration
    • Hotel Reservations
  • Abstracts
    • Abstract Submission Process
    • Presentation Schedules
    • Abstract Submission Guidelines
    • Presentation Guidelines
    • Undergraduate Abstract Locator (2020)
    • Graduate Abstract Locator (2020)
    • Faculty Abstract Locator (2020)
  • Travel Awards
  • Resources
    • App
    • Award Winners
    • Code of Conduct-AAAS Meetings
    • Code of Conduct-ERN Conference
    • Conference Agenda
    • Conference Materials
    • Conference Program Books
    • ERN Photo Galleries
    • Events | Opportunities
    • Exhibitor Info
    • HBCU-UP/CREST PI/PD Meeting
    • In the News
    • NSF Harassment Policy
    • Plenary Session Videos
    • Professional Development
    • Science Careers Handbook
    • Additional Resources
    • Archives
  • Engage
    • Webinars
    • Video Contest
    • Video Contest Winners
    • ERN 10-Year Anniversary Videos
    • Plenary Session Videos
  • Contact Us
  • App View

Binding Studies of Mutated C2 Domain in Coagulation Factor VIII

Undergraduate #141
Discipline: Chemistry and Chemical Sciences
Subcategory: Biochemistry (not Cell and Molecular Biology and Genetics)

Stephanie Thompson - Georgia State University
Co-Author(s): Michelle Wuerth and Marcus Carlson, Western Washington University, Bellingham, WA



Hemophilia A is a genetic disorder in which the blood is unable to clot normally and is caused by the lack or absence of coagulation Factor VIII. Factor VIII (fVIII) is a glycoprotein functioning as a cofactor. The most effective treatment for hemophilia A patients include infusions of plasma-derived or recombinant fVIII. A major impediment of fVIII replacement therapy is the development of inhibitory antibodies. The C2 domain of fVIII is a highly immunogenic domain and is essential to the binding of activated platelet surfaces. Once inhibitory antibodies are produced, the C2 domain of fVIII binds to the inhibitory antibodies rather than activated platelets. Mechanistic investigations of the inhibitory antibodies suggest that it prevents the binding of fVIII to phospholipids which aid in the coagulation process. Several residues of the C2 domain are thought to be responsible for binding to these antibodies including Arg2320. Mutations of this residue and binding affinity studies potentially aid in developing new treatments designed to improve blood clotting in hemophilia A patients. Site-directed mutagenesis was used to generate three different point mutants of Arg2320 (R2320S, R2320T, and R2320M). Each point mutant was over expressed and purified from E. coli. Preliminary membrane binding studies (ELISAs) were performed to further understand the role of Arg2320 in binding to platelet surfaces. The results of this study concluded that residue R2320, when mutated, did bind less to blood platelet like membranes. Future work include supplementary binding assays and stability test to further gather data on this residue.

Funder Acknowledgement(s): National Science Foundation

Faculty Advisor: P. Clint Spiegel,

ERN Conference

Celebrating 10 years of ERN!

What’s New

  • Webinars
  • Events|Opportunities
  • AAAS CEO Comments on Social Unrest, Racism, and Inequality
  • Maintaining Accessibility in Online Teaching During COVID-19
  • In the News
  • #ShutDownSTEM
  • HBCU/CREST PI/PD Meeting

Conference Photos

ERN Conference Photo Galleries

Awards

ERN Conference Award Winners

Checking In

Navigation

  • About the ERN Conference
  • Partners/Supporters
  • Abstracts
  • Travel Awards
  • Conference Registration
  • Exhibitor Registration
  • Hotel Reservations

nsf-logo[1]

This material is based upon work supported by the National Science Foundation (NSF) under Grant No. DUE-1930047. Any opinions, findings, interpretations, conclusions or recommendations expressed in this material are those of its authors and do not represent the views of the AAAS Board of Directors, the Council of AAAS, AAAS’ membership or the National Science Foundation.

AAAS

1200 New York Ave, NW Washington,DC 20005
202-326-6400
Contact Us
About Us

The World's Largest General Scientific Society

Useful Links

  • Membership
  • Careers at AAAS
  • Privacy Policy
  • Terms of Use

Focus Areas

  • Science Education
  • Science Diplomacy
  • Public Engagement
  • Careers in STEM

 

  • Shaping Science Policy
  • Advocacy for Evidence
  • R&D Budget Analysis
  • Human Rights, Ethics & Law
© 2021 American Association for the Advancement of Science